Schizophrenia

2022 - 8 - 29

Post cover
Image courtesy of "Myjoyonline.com"

From Eric's Diary: Schizophrenia - an underlying cause of needless ... (Myjoyonline.com)

I love listening to radio. You will be wrong to say it is because I am a journalist. Radio was forced down my ears as a toddler through teenage.

“We have to let the proprietor understand that it is the school fees we have been paying that she uses to expand the infrastructure, so we have shares in the school. Fortunately, through the fitness to practice initiative, the Medical and Dental Council as well as the Nursing and Midwifery Council are able to weed them out of the system. The deceased is suspected to have attempted to steal a cub. Although he worked for a quarter of the required period, he went about shouting his voice hoarse that because he has not decided to quit, he is entitled to the full compensation. You must have observed that whether in church, at the office, in the family or in your area, there is this individual who, even when you need a life-saving assistance, and you are asked to speak to, you instantly wave your hands in disapproval. Per the contract, he would be entitled to a set amount if he works for a stated number of months. That husband, who will not allow you to work or express your opinion on domestic issues and spanks you at the least or no basis for provocation, could be a suspect. It is said to be uncommon for schizophrenia to be diagnosed in a person younger than 12 or older than 40. Before I proceed, I also wish to suggest that if you are a parent who barely satisfies the needs of your dependents, beware of which family you leave your child with to pass the time. When I left Radio Gold and I was looking for options, I tuned in to Joy FM and got hooked. Again, when it pleased the Lord to bless me with a car, the first accessory I looked out for was the radio. In explaining mental health itself, this is what the WHO has on its website, “it is critically important for everyone, everywhere, and goes beyond the mere absence of a mental health condition.

Schizophrenia & transitioning from PP1M to PP3M. | NDT (Dove Medical Press)

Multiple therapeutic options are available to treat patients diagnosed with schizophrenia, including oral antipsychotics (OAPs) and long-acting injectable ...

The sensitivity analyses confirmed findings of the main analysis, with a significantly lower risk of relapse observed in patients adequately treated with PP1M before transitioning to PP3M who were followed for ≥6 months (33% relative risk reduction) and ≥24 months (26% relative risk reduction) compared with patients who were not adequately treated. This created a proxy for investigating the effects of adequate treatment (randomized) and inadequate treatment (nonrandomized) with PP1M prior to transition to PP3M in the post hoc analysis. In this real-world analysis of claims data, adequate treatment with PP1M before transitioning to PP3M was associated with significantly lower relapse rates and delayed time to relapse among patients diagnosed with schizophrenia. In this analysis of Medicaid claims data from real-world patients with schizophrenia, patients who were adequately treated with PP1M before transitioning to PP3M had a significantly lower risk of relapse (35% relative risk reduction) compared with patients who were not adequately treated. Available from: [http://www.medicaidmentalhealth.org/_assets/file/Guidelines/2019%20Psychotherapeutic%20Medication%20Guidelines%20for%20Adults%20with%20References_06-04-20.pdf](http://www.medicaidmentalhealth.org/_assets/file/Guidelines/2019%20Psychotherapeutic%20Medication%20Guidelines%20for%20Adults%20with%20References_06-04-20.pdf). In a recent survey of psychiatrists and their patients with schizophrenia, patients with fewer relapses in the 12-month span prior to the survey experienced better quality of life, higher levels of employment, fewer symptoms, and greater participation in social interactions. In the first sensitivity analysis, risk of relapse was 33% lower in the AT compared with the NAT cohort (HR: 0.67 [95% CI, 0.54–0.83]) ( The second sensitivity analysis included patients with ≥24 months of follow-up data to observe patients with longer follow-up time and treatment duration. Patients were matched on propensity score to 2 primary PP3M patient cohorts: (1) AT, defined as patients treated with PP1M for ≥4 months (≥5 injections), of which the last 2 doses were the same and the PP3M initiation dose met the corresponding dose conversion from PP1M to PP3M, or (2) NAT, defined as patients who received ≤2 or no PP1M doses. [14](#cit0014) Because of the long-acting nature of PP3M, it may be difficult to adjust the dose after initiating treatment because changes in plasma concentration will not be fully evident for several months (compared with days or weeks for OAPs). [1–3](#cit0001 cit0002 cit0003) Paliperidone palmitate (PP) is an LAI that has been shown to be effective in maintaining symptom control, reducing the risk of relapse, and delaying time to relapse in schizophrenia. Over a two-year time period, the study showed that people who received four or more months of treatment with PP1M before transitioning to PP3M experienced fewer relapses than people who received less than two months of treatment with PP1M before transitioning to PP3M.

Paliperidone Palmitate Associates With Fewer Hospitalization ... (Psychiatry Advisor)

Earlier initiation of paliperidone palmitate associated with fewer events of treatment failure due to hospitalization or arrest compared with OAPs.

[Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: a post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study.](https://www.sciencedirect.com/science/article/pii/S0920996422002870?via%3Dihub) Schizophr Res. Study authors concluded, “Our results suggest that treatment with PP may delay time to first major treatment failure (hospitalization or arrest/incarceration), which could have profound personal, societal, and economic impact. During the first randomization, 5.1% of PP recipients had treatment failure due to psychiatric hospitalization and 2.6% due to arrest or incarceration compared with 7.0% and 2.5% among OAP recipients, respectively. Patients had a 2-month run-in period, followed by randomization to receive PP (n=78) or OAP (n=157) for 9 months, and 9-month re-randomization to PP or OAP (PP/PP, n=49; OAP/PP, n=57; OAP/OAP, n=63). There was no significant difference in the risk for treatment failure between cohorts during the first randomization period (hazard ratio [HR], 1.04; 95% CI, 0.47-2.16; P =.918). Patients who were randomized to receive PP/PP (n=49) or OAP/OAP (n=63) had an 18-month extension on treatment. doi:10.1016/j.schres.2022.07.015 During the treatment extension, 4.1% of the PP/PP group were hospitalized, 12.7% of the OAP/OAP group were hospitalized, and 4.8% of the OAP/OAP group were arrested or incarcerated. During the second randomization period, the rates of treatment failure due to hospitalization or arrest or incarceration were 0% and 0% for PP/PP, 3.5% and 0% for OAP/PP, and 12.7% and 3.2% for OAP/OAP, respectively. In the final extension, PP/PP was associated with decreased risk for treatment failure compared with OAP/OAP (HR, 0.37; 95% CI, 0.12-0.95; P =.045). In the second randomization period, among patients who received OAP during the first randomization, switching to PP was associated with decreased risk for treatment failure compared with patients who remained on OAP (HR, 0.20; 95% CI, 0.03-0.92; P =.002). Earlier initiation of paliperidone palmitate (PP) was associated with fewer events of treatment failure due to hospitalization, arrest, or incarceration compared with oral antipsychotics (OAPs) among patients with schizophrenia.

Explore the last week